PowderMed's Vaccines: Out of Chiron, Into the Clinic

The £542 million ($959 million) that Chiron Corp. spent acquiring PowderJect Pharmaceuticals PLC in mid-2003 was a move by the US company to get its hands on PowderJect's thriving Fluvirin influenza vaccine business and, oddly enough, bulk up its infrastructure on its home soil.

The £542 million ($959 million) that Chiron Corp. spent acquiring PowderJect Pharmaceuticals PLC in mid-2003 was a move by the US company to get its hands on PowderJect's thriving Fluvirin influenza vaccine business and, oddly enough, bulk up its infrastructure on its home soil. PowderJect's acquisitive history--it got Fluvirin from Celltech Medeva PLC in 2000 [See Deal]—had made it into the world's largest independent vaccines company, complete with a solid US distribution network that complemented Chiron's European presence [See Deal]. The combination of the firms' assets was designed to allow Chiron to compete among the Big Pharma at the top of the vaccines ladder. (See "Chiron/PowderJect: US Snaps Up Europe's Best," In Vivo Europe Rx, July 2003. Also see "Chiron/PowderJect: US Snaps Up Europe's Best" - In Vivo, 1 July, 2003..) So far the move has paid off for Chiron. In 2003, the firm sold $332 million worth of flu vaccines, of which $219 million came from Fluvirin sales, nearly double the £67 million in PowderJect's fiscal year 2002.

Lost in the transatlantic shuffle were a handful of modestly profitable travelers' vaccines and PowderJect's original raison d'être: the powder-injection...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By 

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy